Saturday 17 October 2026
Export PTIX’s income statement to Excel — free account
Atrinsic Inc.
PTIX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 61.3% and free cash flow grew 46.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.75
0.05
−6.25%
Follow PTIX
Atrinsic Inc. (PTIX) P/E ratio
As of 15 October 2026, Atrinsic Inc. (PTIX) trades at a P/E ratio of 0.3×. Over the past ten years it has ranged from 0.0× (March 2026) to 0.8× (April 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.8×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BBLG Bone Biologics Corp. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| CYTOF Altamira Therapeutics Ltd. compare | n/m |
| SPRC SciSparc Ltd. compare | n/m |
| CARM Carisma Therapeutics Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| MLEC Moolec Science SA compare | n/m |
| ABPO Abpro Holdings Inc. compare | 0.2× |
| PTIX Atrinsic Inc. | 0.3× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)